TripSit home
← All factsheets

MDMA

Also known as molly, ecstasy, adam, xtc, mandy, x, md

Chemical Name

MDMA

Aliases

molly, ecstasy, adam, xtc, mandy, x, md

Categories

Stimulant, Psychedelic, Empathogen, Habit-forming, Common

Summary

The drug has been associated with cognitive decline when taken in excess. The drug is used in a variety of ways, such as parties, music festivals, psychedelic therapy, and more. The drug often sold as powder or in pressed pills, and may be adulterated with other similar chemicals.

Detection

1-3 days single use, 3-5 days heavy use

General-advice

It is recommended to wait at minimu multiple months between MDMA rolls.

Marquis

Black (may have purple tint)

Dosage Note

NOTE: Higher dosages may increase neurotoxic effects

Dosages

Chart shows bounded mass ranges in mg. See the table for all doses.

Light

Common

Strong

Heavy

Insufflated

30-70mg

70-120mg

120-165mg

165mg+

Oral

40-75mg

75-125mg

125-175mg

175mg+

Rectal

30-70mg

70-120mg

120-165mg

165mg+

Durations

Onset

Duration

After Effects

Oral

20m to 1h 10m

3h to 5h

1h to 72h

Known Combinations

Combination information is sourced from our drug database. Sources can be found on our wiki. The nice combo chart can be found on tripsit.me/combo.

Dangerous (6)

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AMT
Dextromethorphan
Lithium
High risk of serotonin syndrome
MAOIs
MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with MDMA will lead to hypertensive crises.
Mephedrone
Risk of serotonin syndrome as both drugs raise serotonin levels. Stimulants also increase the neurotoxic effects of MDMA, in addition to concerns of high blood pressure and unnecessary strain on the heart. As well as potentially causing anxiety and greater physical discomfort due to the combination.
Tramadol
Tramadol and stimulants both increase the risk of seizures.

Unsafe (2)

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

PCP
This combination can easily lead to hypermanic states
Pregabalin
There is a significant risk of seizures from this combination. Amphetamines increase respiration rate allowing for a higher dose of sedatives than normal. If amphetamines wears off first, recreational dosages of pregabalin may overcome the individual and cause respiratory arrest. Both substances at recreational dosages cause strain of the heart and may lead to further dangerous heart complications. Medical dosages are not reported to be a concern

Caution (10)

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

2C-T-x
5-MeO-xxT
Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care
Alcohol
The combination of MDMA and alcohol may increase strain on the cardiovascular system and lead to increased alcohol consumption. MDMA may also impair one's ability to recognize their level of drunkenness, leading to increased alcohol consumption and poor decision-making. Alcohol may also increase the risk of dehydration and hyperthermia (increased body temperature) when combined with MDMA.
Amphetamines
This combination of stimulants will increase strain on the heart, may cause some physical discomfort, and has the chance to cause cardiovascular issues. The anxiogenic and focusing effects of stimulants can increase the chance of unpleasant thought loops and make the experience more uncomfortable, this combination raises these chances. Amphetamines will increase the neurotoxic effects of MDMA, in addition to causing further concerns of hyperthermia due to the inherent nature of the combination. It will also raise one's body temperature, also likely making the combination more neurotoxic.
Caffeine
Caffeine is not really necessary with MDMA and increases any neurotoxic effects from MDMA
Cocaine
Cocaine blocks some of the desirable effects of MDMA while increasing the risk of heart attack.
DOx
The combined stimulating effects of the two can be uncomfortable. Coming down on the MDMA while the DOx is still active can be quite anxiogenic.
GHB/GBL
Large amounts of GHB/GBL may overwhelm the effects of MDMA on the comedown.
MXE
There have been reports of risky serotonergic interactions when the two are taken at the same time, but MXE taken to the end of an MDMA experience does not appear to cause the same issues.
NBOMes

Low Risk & Synergy (8)

These drugs work together to cause an effect greater than the sum of its parts, and they aren't likely to cause an adverse or undesirable reaction when used carefully. Additional research should always be done before combining drugs.

2C-x
Cannabis
Large amounts of cannabis may cause strong and somewhat unpredictable experiences in combination with MDMA. Cannabis should be saved for towards the end of the experience if possible.
DMT
Ketamine
No unexpected interactions, though likely to increase blood pressure but not an issue with sensible doses. Moving around on high doses of this combination may be ill advised due to risk of physical injury.
LSD
Mescaline
Mushrooms
Nitrous

Low Risk & No Synergy (1)

Effects are additive. The combination is unlikely to cause any adverse or undesirable reaction beyond those that might ordinarily be expected from these drugs.

Opioids

Low Risk & Decrease (2)

Effects are subtractive. The combination is unlikely to cause any adverse or undesirable reaction beyond those that might ordinarily be expected from these drugs.

Benzodiazepines
SSRIs

Sources

Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity - http://www.ncbi.nlm.nih.gov/pubmed/10619665Involvement of free radicals in MDMA-induced neurotoxicity in mice. - http://www.ncbi.nlm.nih.gov/pubmed/11435997Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'. - http://www.ncbi.nlm.nih.gov/pubmed/15370888The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals - http://www.ncbi.nlm.nih.gov/pubmed/15474609MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. - http://www.ncbi.nlm.nih.gov/pubmed/16220332Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB) - http://www.ncbi.nlm.nih.gov/pubmed/162341323,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. - http://www.ncbi.nlm.nih.gov/pubmed/16541247The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans - http://www.ncbi.nlm.nih.gov/pubmed/17047932Neurogenic bladder and chronic urinary retention associated with MDMA abuse. - http://www.ncbi.nlm.nih.gov/pubmed/18570171THC Prevents MDMA Neurotoxicity in Mice - http://www.ncbi.nlm.nih.gov/pubmed/20174577Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). - http://www.ncbi.nlm.nih.gov/pubmed/20378736Neurotoxicity of ecstasy (MDMA): an overview - http://www.ncbi.nlm.nih.gov/pubmed/20420572MDMA: interactions with other psychoactive drugs - http://www.ncbi.nlm.nih.gov/pubmed/21756931MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. - http://www.ncbi.nlm.nih.gov/pubmed/21924843MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral... - http://www.ncbi.nlm.nih.gov/pubmed/21952668MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase. - http://www.ncbi.nlm.nih.gov/pubmed/23179355MDMA Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. - http://www.ncbi.nlm.nih.gov/pubmed/23457892Cocaine potentiates MDMA-induced oxidative stress but not dopaminergic neurotoxicity in mice: implications for the pathogenesis of free radical - http://www.ncbi.nlm.nih.gov/pubmed/23681166MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. - http://www.ncbi.nlm.nih.gov/pubmed/2452449MDMA, cortisol, and heightened stress in recreational ecstasy users. - http://www.ncbi.nlm.nih.gov/pubmed/25014666A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. - http://www.ncbi.nlm.nih.gov/pubmed/7516800Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. - http://www.ncbi.nlm.nih.gov/pubmed/7542394MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). - http://www.ncbi.nlm.nih.gov/pubmed/7945733Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. - https://www.ncbi.nlm.nih.gov/pubmed/240063183,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. - http://www.ncbi.nlm.nih.gov/pubmed/11752122Putting an Ecstasy test kit to the test: harm reduction or harm induction? - http://www.ncbi.nlm.nih.gov/pubmed/14594341MDMA Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. - http://www.ncbi.nlm.nih.gov/pubmed/16574714Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria. - http://www.ncbi.nlm.nih.gov/pubmed/17881526Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. - http://www.ncbi.nlm.nih.gov/pubmed/19562632Neurotoxicity of ecstasy (MDMA): an overview. - http://www.ncbi.nlm.nih.gov/pubmed/20420572Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats - http://www.ncbi.nlm.nih.gov/pubmed/21615721Neurotoxicity of ecstasy and its metabolites in human dopaminergic differentiated SH-SY5Y cells. - http://www.ncbi.nlm.nih.gov/pubmed/23194825Neuroprotective properties of melissa officinalis L. Extract against ecstasy-induced neurotoxicity. - http://www.ncbi.nlm.nih.gov/pubmed/23671824Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. - http://www.ncbi.nlm.nih.gov/pubmed/24006318MDMA, cortisol, and heightened stress in recreational ecstasy users - http://www.ncbi.nlm.nih.gov/pubmed/25014666History of MDMA - http://www.mdma.net/merck/history-ecstasy.htmlStudy associating long-term serotonergic injury from use of MDMA - http://www.ncbi.nlm.nih.gov/pubmed/7643196Even after abstaining as long as 2.5 years, verbal memory deficits were still present in ex-mdma abuserd, indicating that the neurotoxicity may have some permanent damage features - http://m.jop.sagepub.com/content/20/2/211.shorthttp://onlinelibrary.wiley.com/doi/10.1002/nrc.20023/abstract Potentiation of (DL)-3,4-methylenedioxymethamphetamine (MDMA)-induced toxicity by the serotonin 2A receptior partial agonist d-lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939